We are live on ! Find out more
STML

Stemline Therapeutics, Inc.
STML

Delisted

STML was delisted on the 9th of June, 2020.

Back to rankings

100 hedge funds and large institutions have $445M invested in Stemline Therapeutics, Inc. in 2019 Q3 according to their latest regulatory filings, with 17 funds opening new positions, 56 increasing their positions, 18 reducing their positions, and 13 closing their positions.

New
Increased
Maintained
Reduced
Closed

211% more repeat investments, than reductions

Existing positions increased: 56 | Existing positions reduced: 18

31% more first-time investments, than exits

New positions opened: 17 | Existing positions closed: 13

4% more funds holding

Funds holding: 96 → 100 (+4)

20% less capital invested

Capital invested by funds: $555M → $445M (-$110M)

67% less funds holding in top 10

Funds holding in top 10: 3 → 1 (-2)

69% less call options, than puts

Call options by funds: $292K | Put options by funds: $932K

Holders
100
Holders Change
+4
Holders Change %
+4.17%
% of All Funds
2.19%
Holding in Top 10
1
Holding in Top 10 Change
-2
Holding in Top 10 Change %
-66.67%
% of All Funds
0.02%
New
17
Increased
56
Reduced
18
Closed
13
Calls
$292K
Puts
$932K
Net Calls
-$640K
Net Calls Change
+$860K

Top Buyers

Rank Fund Capital Flow
1
AllianceBernstein
AllianceBernstein
Tennessee
+$20.5M
2
Manulife (Manufacturers Life Insurance)
Manulife (Manufacturers Life Insurance)
Ontario, Canada
+$20M
3
EAM
Eventide Asset Management
Massachusetts
+$12.7M
4
FCM
Farallon Capital Management
California
+$10.5M
5
Alkeon Capital Management
Alkeon Capital Management
New York
+$8.05M

Top Sellers

Rank Fund Capital Flow
1
T. Rowe Price Associates
T. Rowe Price Associates
Maryland
-$7.62M
2
SSA
Schonfeld Strategic Advisors
New York
-$6.86M
3
Citadel Advisors
Citadel Advisors
Florida
-$4.52M
4
Point72 Asset Management
Point72 Asset Management
Connecticut
-$3.94M
5
FI
Fosun International
China
-$3.21M
Name Holding Trade Value Shares
Change 		Change in
Stake
Ameriprise
51
Ameriprise
Minnesota
$579K +$158K +12,100 +28%
RhumbLine Advisers
52
RhumbLine Advisers
Massachusetts
$566K +$25.4K +1,945 +4%
Allianz Asset Management
53
Allianz Asset Management
Germany
$522K +$377K +28,788 +135%
VEA
54
Virtus ETF Advisers
New York
$509K -$108K -8,221 -14%
New York State Common Retirement Fund
55
New York State Common Retirement Fund
New York
$494K +$118K +9,000 +23%
Squarepoint
56
Squarepoint
New York
$479K +$602K +45,981 New
GCP
57
GSA Capital Partners
United Kingdom
$479K +$602K +46,033 New
TI
58
Telemetry Investments
New York
$416K +$78.5K +6,000 +18%
California Public Employees Retirement System
59
California Public Employees Retirement System
California
$411K +$128K +9,800 +33%
FAM
60
Fred Alger Management
New York
$364K +$458K +35,000 New
Verition Fund Management
61
Verition Fund Management
Connecticut
$364K +$458K +35,000 New
Los Angeles Capital Management
62
Los Angeles Capital Management
California
$340K +$282K +21,540 +193%
CS
63
Credit Suisse
Switzerland
$333K +$175K +13,387 +72%
BG
64
Bellevue Group
Switzerland
$328K +$412K +31,500 New
UBS AM
65
UBS AM
Illinois
$328K +$179K +13,678 +77%
AIG
66
American International Group
New York
$295K +$37K +2,831 +11%
Bank of America
67
Bank of America
North Carolina
$292K -$558K -42,666 -60%
CHAM
68
Clear Harbor Asset Management
Connecticut
$256K +$322K +24,625 New
Barclays
69
Barclays
United Kingdom
$248K -$28.2K -2,153 -8%
HSBC Holdings
70
HSBC Holdings
United Kingdom
$228K +$286K +21,888 New
Morgan Stanley
71
Morgan Stanley
New York
$225K +$171K +13,108 +155%
CSS
72
Cubist Systematic Strategies
Connecticut
$221K +$277K +21,201 New
WMSA
73
Weiss Multi-Strategy Advisers
New York
$208K +$262K +20,000 New
MIM
74
MetLife Investment Management
New Jersey
$192K – – –
VOYA Investment Management
75
VOYA Investment Management
Georgia
$180K +$17.2K +1,313 +8%
1 2
3
4 5

STML Hedge Fund Activity: Q3 2019 in Review

100 of the 4,560 institutional investors tracked by Wall St. Rank reported a position in Stemline Therapeutics, Inc. (STML) for Q3 2019, worth a combined $445M — down 20% from $555M a quarter earlier.

Buyers outnumbered sellers: 17 funds opened new STML positions and 13 closed out — a net gain of 4 holders — while 56 added to existing stakes and 18 trimmed.

The largest buyer was AllianceBernstein, adding an estimated $20.5M. The largest seller was T. Rowe Price Associates, cutting an estimated $7.62M.

  • 100 institutional investors held Stemline Therapeutics, Inc. (STML) as of Q3 2019, up from 96 in Q2 2019.
  • Funds reported $445M of Stemline Therapeutics, Inc. stock for Q3 2019, down 20% quarter-over-quarter.
  • 17 funds opened new Stemline Therapeutics, Inc. positions in Q3 2019 and 13 closed out, a net change of +4 holders.
  • The largest Stemline Therapeutics, Inc. buyer in Q3 2019 was AllianceBernstein, an estimated $20.5M added.
  • The largest Stemline Therapeutics, Inc. seller in Q3 2019 was T. Rowe Price Associates, an estimated $7.62M sold.

Based on aggregated 13F filings for Q3 2019.